Heritage Bio Labs
Research Library
Explore 411 articles about peptides, research compounds and related topics, with links to the original studies.
Find articles
Matching articles
Showing 97–108 of 134 articles · Explore study findings
- Explore study findings
What FDA found about human exposure to PEG-MGF
PEG-MGF is a name for a synthetic mechano growth factor-related peptide linked to polyethylene glycol, or PEG. The name is related to research on insulin-like growth factor I, or IGF-I.
PEG-MGF1 source (2026)
- Explore study findings
What a withdrawn compounding nomination means
PEG-MGF refers to a synthetic MGF-related peptide joined to polyethylene glycol, or PEG. The FDA has tracked it separately from unmodified mechano growth factor. Its 2026 records illustrate the difference between a nomination to a compounding list and evidence supporting an approved drug.
PEG-MGF3 sources (2026)
- Explore study findings
Why chemical modification can change more than persistence
PEG-MGF is a synthetic MGF-related peptide attached to polyethylene glycol. An older laboratory study examined a different substance, PEG-linked full-length IGF-I. It asked a useful question for interpreting any modified molecule.
PEG-MGF2 sources (2011, 2026)
- Explore study findings
What Pinealon Changed in Neurons Grown From Older Donor Cells
Pinealon is a synthetic three-amino-acid peptide also known as EDR. Researchers have studied it in models of nerve cells and aging.
Pinealon1 source (2024)
- Explore study findings
What Participants Reported After the Bremelanotide Trials
Bremelanotide, also called PT-141, was evaluated in the RECONNECT trials for hypoactive sexual desire disorder. An older exit-study report examined what some trial participants said about their experience.
PT-1412 sources (2021, 2026)
- Explore study findings
What TRIUMPH-1 established about average weight change
Retatrutide activates the GIP, GLP-1 and glucagon receptors, the three targets behind its description as a triple agonist. The “GLP-3” catalog wording refers to the entry, while the scientific names identify the receptors studied.
RETA GLP-32 sources (2025, 2026)
- Explore study findings
Why TRIUMPH-2 enrolled adults with type 2 diabetes
Retatrutide is an investigational peptide that activates GIP, GLP-1 and glucagon receptors. “GLP-3” is catalog wording for this triple agonist. The 2026 TRIUMPH-2 report asked what happened to body weight in participants who had both type 2 diabetes and excess body weight.
RETA GLP-32 sources (2026)
- Explore study findings
What retatrutide blood samples reveal about changing fuel use
Retatrutide is an investigational peptide that activates the GIP, GLP-1 and glucagon receptors. The “GLP-3” label refers to the catalog entry.
RETA GLP-31 source (2026)
- Explore study findings
What a retatrutide outcomes trial can establish about kidney events
Retatrutide is an investigational peptide that acts on GIP, GLP-1 and glucagon receptors. IGF-1 LR3 is an engineered, extended version of the insulin-like growth factor 1 protein. This catalog entry names the two together.
RETA / IGF-1 LR33 sources (1995–2026)
- Explore study findings
What a Selank Rat Study Found About GABA Related Gene Expression
Selank is a synthetic peptide based on tuftsin. It has been studied in relation to GABA, a neurotransmitter that participates in regulating nervous system activity. An older laboratory study tested whether gene expression in rat brain tissue changed after exposure to Selank.
Selank1 source (2016)
- Explore study findings
Why two approval records describe different ingredients
Semaglutide is a modified peptide that activates the GLP-1 receptor. IGF-1 LR3 is an engineered, extended version of the insulin-like growth factor 1 protein. This entry names both molecules together.
SEMA / IGF-1 LR33 sources (2023–2026)
- Explore study findings
What IGF-1 LR3 did in a lab-made skin model
Semaglutide is a peptide that activates the GLP-1 receptor. IGF-1 LR3 is an engineered version of a growth-factor protein. A 2026 tissue-engineering study used IGF-1 LR3 to investigate how cells build a supporting matrix in reconstructed skin tissue.
SEMA / IGF-1 LR32 sources (2026)
Browse by product
- A4 Amyloid Beta6 articles
- ACE-0316 articles
- ACE-0836 articles
- Adipotide6 articles
- AICAR6 articles
- AOD-96046 articles
- ARA-2906 articles
- BPC-1576 articles
- BPC-157 / TB-5006 articles
- Cagrilintide7 articles
- CJC-1295 (No DAC) / GHRP-26 articles
- CJC-1295 (No DAC) / GHRP-66 articles
- CJC-1295 (No DAC) / Ipamorelin6 articles
- CJC-1295 No DAC6 articles
- CJC-1295 With DAC6 articles
- DSIP6 articles
- Epitalon6 articles
- Follistatin 3156 articles
- Follistatin 3446 articles
- Fragment 176-1916 articles
- GHK-Cu6 articles
- GHRP-26 articles
- GHRP-66 articles
- GLOW 2 Blend6 articles
- GLOW Blend6 articles
- GLP-1 SEMA6 articles
- GLP-2 TIRZ6 articles
- Glutathione6 articles
- HCG6 articles
- Hexarelin6 articles
- Human Relaxin-26 articles
- IGF-1 DES 1,36 articles
- IGF-1 Human6 articles
- IGF-2 LR36 articles
- IGF-DES 1,36 articles
- IGF-LR36 articles
- Ipamorelin6 articles
- Kisspeptin-106 articles
- KLOW Blend6 articles
- KPV6 articles
- Lipopeptide6 articles
- Liraglutide6 articles
- Melanotan II5 articles
- MGF6 articles
- MOTS-C6 articles
- MSC Exosomes6 articles
- Myostatin6 articles
- Myostatin HMP (GDF8)6 articles
- Oxytocin7 articles
- PEG-MGF6 articles
- Pinealon6 articles
- PT-1416 articles
- RETA / IGF-1 LR36 articles
- RETA GLP-36 articles
- Selank6 articles
- SEMA / IGF-1 LR36 articles
- Semax6 articles
- Sermorelin6 articles
- SLU-PP-3326 articles
- SNAP-86 articles
- Survodutide7 articles
- TB-5006 articles
- Tesamorelin6 articles
- Thymosin Alpha-16 articles
- TIRZ / IGF-1 LR36 articles
- TIRZ GLP-26 articles
- Trevogrumab6 articles
- Triptorelin GnRH6 articles
